| Legend Biotech is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Co.'s primary product candidate, ciltacabtagene autoleucel, or cilta-cel (referred to as LCAR- B38M for purposes of its LEGEND-2 trial), is a chimeric antigen receptor T cell (CAR-T) therapy it is jointly developing with its partner, Janssen Biotech, Inc. for the treatment of multiple myeloma. In addition to cilta-cel, Co. has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma. The LEGN YTD return is shown above.
The YTD Return on the LEGN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether LEGN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LEGN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.